Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Current Assets (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Current Assets readings, the most recent being $12.2 million for Q1 2026.

  • On a quarterly basis, Current Assets fell 55.22% to $12.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $12.2 million, a 55.22% decrease, with the full-year FY2025 number at $12.2 million, down 81.18% from a year prior.
  • Current Assets hit $12.2 million in Q1 2026 for Atara Biotherapeutics, roughly flat from $12.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $347.0 million in Q2 2022 to a low of $12.2 million in Q1 2026.
  • Median Current Assets over the past 5 years was $101.9 million (2023), compared with a mean of $133.9 million.
  • Biggest five-year swings in Current Assets: fell 22.61% in 2024 and later plummeted 81.18% in 2025.
  • Atara Biotherapeutics' Current Assets stood at $295.1 million in 2022, then plummeted by 65.48% to $101.9 million in 2023, then tumbled by 36.3% to $64.9 million in 2024, then plummeted by 81.18% to $12.2 million in 2025, then decreased by 0.32% to $12.2 million in 2026.
  • The last three reported values for Current Assets were $12.2 million (Q1 2026), $12.2 million (Q4 2025), and $18.4 million (Q3 2025) per Business Quant data.